Introduction {#S1}
============

Human cytomegalovirus (HCMV), officially referred to as human herpesvirus 5 (HHV5), is one of nearly 100 known herpesviruses and is subclassified as a beta-herpesvirus. The seroprevalences vary with respect to socioeconomic background. Generally, the virus is widespread ([@B36]), and serum positive for infection in the general population has been estimated to be 83% ([@B292]). Moreover, seronegativity does not show a complete correlation with negativity for HCMV DNA in CD34^+^ hematopoietic progenitor cells (HPCs) ([@B126]). Transmission of primary infection usually occurs via intrauterine ([@B25]), breast milk ([@B93]), and contaminations exposure routes (such as saliva or genital secretions) ([@B126]; [@B180]). Reactivation occurs from latency, the sources of which are CD34^+^ HPCs and CD14^+^ monocytes ([@B173]), often after blood transfusion and organ transplantation ([@B286]). HCMV infection in healthy individuals is often mild or asymptomatic. By contrast, it is highly pathogenic among congenitally infected infants and immunocompromised patients, such as transplant recipients ([@B152]). Universal infection of HCMV and persistent lifelong infection suggest that HCMV primary infection has to negotiate a balance with the host. The virion-carried molecules are served as readily available mediators that facilitate viral survival. In this review, the significance of the factors packaged in the HCMV virion will be discussed.

HCMV Structure {#S2}
==============

Genome {#S2.SS1}
------

The HCMV genome, the largest among nine human herpesviruses, is a linear double-stranded DNA containing 230 to 240 k base pairs ([@B59]; [@B62]; [@B28]). The viral genome comprises two unique regions termed unique long (UL) and unique short (US), and these two domains are flanked by a pair of inversely repeated sequences, forming a genome configuration known as TRL-UL-IRL-IRS-US-TRS.

A few hurdles arise when analyzing the HCMV genome sequence and associated virology. First, the laboratory passaged strains AD169 and Towne following subsequent culture accumulate substantial deletions, especially in the UL/b' region, and compensated insertions of several repeats in the long terminal region in comparison to clinically isolated viruses such as Toledo ([@B42]). The UL/b' gene products pUL133--pUL138 are associated with latency, reactivation, and activation of the expression of certain genes in an interdependent manner with pUL97 ([@B202]; [@B146]). Additionally, the UL/b' region has been reported to be involved in NK cell evasion ([@B256]). Merlin and Toledo showed stronger ability against NK cell immunity than AD169 and Towne ([@B256]). *In vitro* analysis demonstrated that HCMV strains that harbor UL/b' were more sensitive to growth defects mediated by maribavir, a pharmacological pUL97 inhibitor ([@B268]). Together, high-passage strains represent a different biological manner than a wild-type virus. Moreover, the laboratory adaptation behavior differs in different HCMV strains. For example, approximately 13 and 15-kbp sequences in the UL/b' region were deleted in Towne and AD169, respectively, compared with Toledo ([@B42]). Second, although the HCMV genome can be cloned and maintained in bacterial artificial chromosomes (BACs), mutations can occur before BAC cloning ([@B241]). The Merlin BAC revealed that this low passage strain contains *RL13* and *UL128* mutations, and repair of these mutations led to impaired replication in fibroblasts ([@B241]). The *RL13* ([@B241]) and *UL128* ([@B207]) genes encode virion glycoproteins. Some patients present a switch in the HCMV population during the course of disease, and the dominantly altered genotypes encompass genes encoding immunomodulatory mediators and glycoproteins ([@B89]). Those genes may be associated with the pathogenesis of HCMV-caused disease ([@B89]). *In vitro* studies using viruses harboring mutations in such genes may provide misleading results regarding the natural behavior of clinically important HCMV. Third, without culture, contamination of cellular DNA that is difficult to eliminate from sequencing causes low viral sequence reads in next generation sequencing. Finally, regardless of immune status, the majority of patients and carriers are infected with mixed HCMV strains ([@B182]; [@B204]; [@B119]). It has been reported that mixed infection with more than one HCMV strain is associated with severe clinical outcomes such as an increased viral load ([@B163]) and progression to CMV disease ([@B48]). Although some degrees of genome instability have appeared in HCMV *in vitro*, a genome reference is still needed. The Merlin strain is a low passage strain and is characterized by relative genomic integrity, allowing to more accurately reflect the wild-type clinical isolates, despite some minor changes, for example, the single-nucleotide substitution in the *RL13* and *UL128* gene ([@B4]; [@B62]; [@B228]; [@B274]).

Capsid ([Table 1](#T1){ref-type="table"}) {#S2.SS2}
-----------------------------------------

The viral capsid provides a layer enclosing the genome. It is an icosahedral structure with a triangulation number T of 16, containing 60 asymmetric units ([@B45]). Sixteen major capsid proteins (MCPs), 16 smallest capsid proteins (SCPs), 5 triplexes (Ta, Tb, Tc, Td, and Te), and 1/3 Tfs exist in each unit. Five or six MCPs form a penton or hexon, with the latter subdivided into P (peripentonal), C (center), and E (edge) hexons as a result of different positions. Near the upper domain of MCP is the SCP. Triplexes are heterotrimers that are composed of Tri1, Tri2A, and Tri2B ([@B282]). The HCMV genome size is approximately 50% longer than the herpes simplex virus type 1 (HSV-1) genome. The diameter of HSV-1 and HCMV capsid is approximately 125 and 130 nm, respectively ([@B33]). The capsid volume of HCMV is slightly larger (about 17%) than HSV-1 ([@B19]). The significant increase in HCMV genome size does not correlate with the slightly larger capsid volume ([@B19]). Hence, the HCMV genome is tightly packaged within the capsid shell and protected by the capsid. This pressurized packaging of the genome is a reasonable strategy for the nucleocapsid to deliver the viral genome into the nucleus by leveraging the internal pressure within the capsid ([@B282]; [@B29]).

###### 

HCMV capsid proteins.

  Protein                               Mapped gene   Kinetics   Function                         References
  ------------------------------------- ------------- ---------- -------------------------------- -------------------------
  Major capsid protein                  *UL86*        Late       Component of capsid              [@B45]; [@B41]; [@B282]
  Smallest capsid protein               *UL48/UL49*   Late       Component of capsid              [@B82]
  Tri1 (minor capsid binding protein)   *UL46?*       Late       Component of triplex on capsid   [@B81]
  Tri2 (minor capsid protein)           *UL85*        Late       Component of triplex on capsid   [@B81]

Tegument ([Table 2](#T2){ref-type="table"}) {#S2.SS3}
-------------------------------------------

Tegument is a link layer between the nucleocapsid and outer envelope, largely composed of diverse proteins that appear unlikely to form a definitive structure. The amorphous layer may contain some RNAs ([@B30]; [@B87]; [@B254]). Although we were intrigued about the biological significance of RNA package in-between the envelope and capsid, the mechanisms underlying how the RNA is enclosed and how they interact with other elements remains largely unexamined. The tegument components are directly delivered into host cytoplasm, allowing the newly infected virus to adapt to the new cellular environment. In contrast, tegument proteins are not readily utilized by reactivated virus, indicating a difference in primary infection and reactivation. Thus, some tegument proteins that play roles in initial infection are true late proteins, which are not expressed at the early phase of the reactivated virus life cycle and are not supposed to assume responsibilities in primary infection. The diverse effects of tegument proteins on HCMV biology ([Table 2](#T2){ref-type="table"}) will dominate the following discussions.

###### 

HCMV tegument proteins.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein                                                             Mapped gene   Kinetics                                                       Function(s)                                                                                                                                                                                                References
  ------------------------------------------------------------------- ------------- -------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------
  pUL23                                                               *UL23*        Early late                                                     ➢ Reduces the STAT-mediated INFγ responses                                                                                                                                                                 [@B1]; [@B68]

  pUL24                                                               *UL24*        Early late and true late                                       ➢ Interacts with other viral proteins                                                                                                                                                                      [@B1]; [@B255]

  pUL25                                                               *UL25*        True late                                                      ➢ Co-localizes with ppUL99 in the perinuclear regions within cytoplasm\                                                                                                                                    [@B14]; [@B290]
                                                                                                                                                   ➢ Prevents Pul26 from degradation\                                                                                                                                                                         
                                                                                                                                                   ➢ Interacts with viral proteins and behaves like a helper---a hub.                                                                                                                                         

  pUL26                                                               *UL26*        Early late                                                     ➢ Be a transcriptional activator of major immediate early enhancer--promoter\                                                                                                                              [@B239]; [@B156]; [@B179]; [@B130]; [@B290]
                                                                                                                                                   ➢ Participate in phosphorylation and stabilization of pp28\                                                                                                                                                
                                                                                                                                                   ➢ Limits ISGylation of interferon-stimulated gene 15 (ISG15)\                                                                                                                                              
                                                                                                                                                   ➢ Blocks NF-κB                                                                                                                                                                                             

  pp150                                                               *UL32*        Late                                                           ➢ Highly immunogenic and pp150 antigen can be detected by ELISA\                                                                                                                                           [@B10]; [@B103]; [@B249]; [@B24]; [@B278]; [@B282]
                                                                                                                                                   ➢ Interact with capsomeres and triplex on capsid and directs translocation of nucleocapsid for further envelopment\                                                                                        
                                                                                                                                                   ➢ Be involved in nuclear targeting, organization of assembly compartment, tegumentation and virion egress during late infection\                                                                           
                                                                                                                                                   ➢ Restricts viral IE gene expression                                                                                                                                                                       

  ppUL35                                                              *UL35*        Predominantly late                                             ➢ Facilitates a proper recycling, transportation and localization of gB\                                                                                                                                   [@B153]; [@B210]; [@B166]
                                                                                                                                                   ➢ Cooperates with pp71 to activate viral gene expression                                                                                                                                                   

  pUL36                                                               *UL36*        Immediate-early                                                ➢ Inhibits caspase-8 activation and thus apoptosis                                                                                                                                                         [@B233]; [@B281]

  pUL38                                                               *UL38*        Early and late                                                 ➢ Modulates cellular metabolism\                                                                                                                                                                           [@B253]; [@B280]; [@B195]; [@B170]; [@B245]; [@B203]
                                                                                                                                                   ➢ Prevents premature cell death by protecting lysosome integrity, relieving endoplasmic reticulum (ER)-mediated apoptosis\                                                                                 
                                                                                                                                                   ➢ Accumulates translational factors by regulating poly(A) binding protein (PABA)                                                                                                                           

  pUL43                                                               *UL43*        Late                                                           ➢ Localizes in perinuclear region in cytoplasm                                                                                                                                                             [@B1]

  HCMV DNA polymerase processivity factor                             *UL44*        Early and late (sumoylated pUL44 was detected at late phase)   ➢ Tethers the catalytic subunit pUL54 onto DNA\                                                                                                                                                            [@B272]; [@B155]; [@B242]; [@B141]; [@B232]; [@B75]
                                                                                                                                                   ➢ Communicates a series of proteins such as cellular nucleolin and viral pUL114 to ensue replication\                                                                                                      
                                                                                                                                                   ➢ Acts concomitantly with IE86 to block p53 activity and thus overcomes cell cycle arrest and apoptosis\                                                                                                   
                                                                                                                                                   ➢ Binds to interferon regulatory factor 3 (IRF3), disassociates IRF3 with NK-κB and prevents subsequent activation of anti-viral genes                                                                     

  Inactive homolog of the large subunit of ribonucleotide reductase   *UL45*        Early                                                          ➢ Catalyzes the dNTP synthesis\                                                                                                                                                                            [@B187]; [@B140]
                                                                                                                                                   ➢ Inhibits RIP1-mediated NF-κB activation                                                                                                                                                                  

  pUL47                                                               *UL47*        Late                                                           ➢ Regulates tegument assembly\                                                                                                                                                                             [@B102]; [@B262]; [@B39]
                                                                                                                                                   ➢ Binds to pUL48 binding protein, which is required to deubiquitylating activity of pIL48                                                                                                                  

  pUL48                                                               *UL48*        Late                                                           ➢ Deubiquitinating activity\                                                                                                                                                                               [@B15]; [@B39]; [@B129]; [@B140]
                                                                                                                                                   ➢ Cooperates with pUL47 to promote disassembly of nucleocapsid and enhance the release of viral DNA from capsid\                                                                                           
                                                                                                                                                   ➢ Guides pUL47 translocation from nucleus to cytoplasm                                                                                                                                                     

  pUL50                                                               *UL50*        Late                                                           ➢ Form the nuclear egress complex\                                                                                                                                                                         [@B56]; [@B205]; [@B158]
                                                                                                                                                   ➢ pUL50 may have a role in maintaining HCMV genome during latency                                                                                                                                          

  pUL53                                                               *UL53*                                                                                                                                                                                                                                                                                  

  DNA polymerase catalytic enzyme                                     *UL54*        Early                                                          ➢ Have polymerase activity, 3′ to 5′ exonuclease activity as well as ribonuclease H activity\                                                                                                              [@B285]
                                                                                                                                                   ➢ Target of antiviral drugs (e.g., ganciclovir)                                                                                                                                                            

  Single-stranded DNA binding protein                                 *UL57*        Early                                                          ➢ Cooperates with other replication initiation proteins to promote DNA synthesis                                                                                                                           [@B7]

  pUL69                                                               *UL69*        Immediate-early                                                ➢ Transactivate certain genes, mediate mRNA nuclear export\                                                                                                                                                [@B276]; [@B92]; [@B289]; [@B263]
                                                                                                                                                   ➢ Binds to UAP56 and URH49, and enhances the nucleocytoplasmic shutting activity\                                                                                                                          
                                                                                                                                                   ➢ Induces G1 block of host cell cycle                                                                                                                                                                      

  pUL71                                                               *UL71*        Early                                                          ➢ Contributes to secondary envelopment                                                                                                                                                                     [@B215]; [@B61]

  pUL72                                                               *UL72*        Late                                                           ➢ Be a homolog of dUTPase (inactive?)                                                                                                                                                                      [@B38]; [@B85]

  pUL76                                                               *UL76*        Immediate-early, late                                          ➢ Regulates *UL77* gene expression\                                                                                                                                                                        [@B270]; [@B113]; [@B53]
                                                                                                                                                   ➢ Modulates gene expression (repress viral replication)\                                                                                                                                                   
                                                                                                                                                   ➢ Activates DNA damage response                                                                                                                                                                            

  pUL77                                                               *UL77*        Early late                                                     ➢ Binds to dsDNA and terminase subunits                                                                                                                                                                    [@B171]; [@B133]

  pUL79                                                               *UL79*        Early late                                                     ➢ Promotes the accumulation of late viral transcripts                                                                                                                                                      [@B190]

  pp71                                                                *UL82*        Immediate-early                                                ➢ Degrades Daxx\                                                                                                                                                                                           [@B121]; [@B208]; [@B259]; [@B257]; [@B74]
                                                                                                                                                   ➢ Transactivation MIE gene\                                                                                                                                                                                
                                                                                                                                                   ➢ Degrades Rb at the onset of lytic infection, promotes cell progression and inhibits apoptosis\                                                                                                           
                                                                                                                                                   ➢ Binds to STING and impedes subsequent activation of TBK1 and IRF3, a method against innate immunity\                                                                                                     
                                                                                                                                                   ➢ Circumvent surface MHC-I expression                                                                                                                                                                      

  pp65                                                                *UL83*        Early late                                                     ➢ Binds to cGAS and IFI16 and interferes with innate immunity\                                                                                                                                             [@B47]; [@B54]; [@B9]; [@B249]; [@B148]; [@B20], [@B21]
                                                                                                                                                   ➢ Mitigate IL-1β via disrupting NF-κB signaling pathway\                                                                                                                                                   
                                                                                                                                                   ➢ Highly immunogenic and elicits adaptive immunity\                                                                                                                                                        
                                                                                                                                                   ➢ May regulates cell cycle\                                                                                                                                                                                
                                                                                                                                                   ➢ Used in the pp65 antigenemia test                                                                                                                                                                        

  pUL84                                                               *UL84*        Early protein synthesized at late time ([@B237])               ➢ Associates with pUL44 and nucleoli in the replication compartments\                                                                                                                                      [@B79]; [@B50]; [@B77]; [@B18]
                                                                                                                                                   ➢ Involved in initiation of viral replication\                                                                                                                                                             
                                                                                                                                                   ➢ Be a transdominant inhibitor of IE2-p86 during gene expression\                                                                                                                                          
                                                                                                                                                   ➢ Facilitates localization of *IRS1* mRNA                                                                                                                                                                  

  pUL93                                                               *UL93*        Early and late                                                 ➢ Required for DNA cleavage packaging                                                                                                                                                                      [@B275]; [@B60]; [@B26]

  pUL94                                                               *UL94*        True late                                                      ➢ Acts as a nucleocytoplasmic shuttling protein and allows correct localization of pUL99 in vAC                                                                                                            [@B192]; [@B193]

  pUL96                                                               *UL96*        Early                                                          Assists pp150 to co-stabilize nucleocapsids                                                                                                                                                                [@B249]

  pUL97                                                               *UL97*        Early late                                                     ➢ Kinase activity (such as phosphorylating (i) antiviral prodrugs, (ii) pUL69 to contributes to the viral mRNA export), (iii) Rb proteins to regulate cell cycle, (iv) nuclear lamina to promote egress\   [@B176]; [@B11]; [@B66]; [@B146]; [@B221]; [@B116]
                                                                                                                                                   ➢ Organizes assembly site\                                                                                                                                                                                 
                                                                                                                                                   ➢ Activate gene expression                                                                                                                                                                                 

  pp28                                                                *UL99*        Late                                                           ➢ Involved in envelope assembly                                                                                                                                                                            [@B229]; [@B47]

  pUL103                                                              *UL103*       Late                                                           ➢ Enhances development of cVAC                                                                                                                                                                             [@B159]; [@B58]

  pIRS1/pTRS1                                                         *IRS1/TRS1*   Early late                                                     ➢ Inactivates RNA-dependent protein kinase R (PKR)\                                                                                                                                                        [@B111]; [@B164]; [@B243]; [@B288]
                                                                                                                                                   ➢ Interacts with pUL44\                                                                                                                                                                                    
                                                                                                                                                   ➢ Binds to autophagic proteins and inhibits the antophage\                                                                                                                                                 
                                                                                                                                                   ➢ Promotes expression of the replication genes                                                                                                                                                             

  pUS22                                                               *US22*        Early late                                                     ➢ Immunogenic and antigenic, and can exert humoral responses                                                                                                                                               [@B57]; [@B1]

  pUS24                                                               *US24*        Immediate-early                                                ➢ Activate viral gene expression                                                                                                                                                                           [@B69]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### DNA Replication {#S2.SS3.SSS1}

Human cytomegalovirus initiates lytic infection by expression of genes in a flow cascade; immediate-early (IE) phase prior to early gene expression and finally late genes are expressed to facilitate virion assemble and release ([@B271]). DNA amplification occurs after early gene expression and before late gene expression. *In vitro* DNA replication usually initiates at 24 to 72 h post infection. *Ori*Lyt, adjacent to *UL57*, occupies a gene region of 2 kb where HCMV DNA replication commences, and there is a region that can regulate both *UL57* transcription and *ori*Lyt activation ([@B127]). Nuclear domain 10 (ND10) is the location for the deposition of viral DNA ([@B107]), which will be discussed later in the section *Roles of pp71 in primary infection and reactivation*. Replication-associated proteins are recruited to the site around the DNA replication compartment that is derived from budding of peripheral ND10 ([@B3]). Six proteins of the replication machinery conserved in members of herpesviridae include pUL54 (DNA polymerase), pUL44 (DNA polymerase processivity factor), pUL57 (single-stranded DNA binding protein), pUL70 (primase), pUL102 (primase-associated factor), and pUL105 (helicase).

An association network is constructed in which pUL44 communicates with a series of proteins to orchestrate viral DNA replication such as cellular nucleolin, viral pUL114, and TRS1 ([@B242], [@B243]). UL112-113 gene products p43 and p84 may play a role in the recruitment of pUL44 ([@B217]). HCMV *UL79*, *UL87*, and *UL95* are expressed early and recruited into the pre-replication complex with pUL44 ([@B114]; [@B191]). pUL44, a HCMV DNA polymerase processivity factor that is capable of tethering the catalytic subunit pUL54 onto DNA to allow continuous elongation of the DNA strand, binds to DNA and pUL54 at two sites located within the N-terminal 309 residues of the UL44 amino acid sequence ([@B272]; [@B155]). Dimerization of pUL44 is critical for its function, and disruption of dimer formation blocks viral progeny production ([@B231]). The nuclear localization signal (NLS) of pUL44 directs its translocation to the nucleus immediately after dimerization ([@B6]). Cellular protein kinase triggers phosphorylation at several lysine residues upstream of NLS in the C-terminal domain of pUL44. Phosphorylation promotes pUL44 nuclear transport, whereas another phosphorylation site, T427, inhibits nuclear targeting once phosphorylated ([@B6]).

An enzyme called ubc9 mediates pUL44 SUMOylation in which pUL44 is covalently conjugated to a small ubiquitin-related modifier (SUMO) molecule in the presence of DNA, and overexpression of SUMO-1 results in increased viral production ([@B232]), although the effects of sumoylated pUL44 on replication remain unexamined. The peak amounts of sumoylated pUL44 were detected in the late phase ([@B232]). Moreover, three transcription start sites of *UL44* were identified, with the proximal and distal promoter being activated in early infection. The middle one initiates *UL44* expression in late infection ([@B143]; [@B112]). Additional roles of both pUL44 and sumoylated pUL44 are indicated but remain unidentified other than replication ([@B112]; [@B232]). pUL44 also shows direct interactions with SWI/SNF, a chromatin remodeling complex. The formation of replication and transcription complexes prior to DNA packaging into the capsid is facilitated by chromatin remodeling processes ([@B196]).

*UL54* is a prototypical early gene that encodes DNA polymerase catalytic enzyme, which is undoubtedly one of the most important proteins during the viral lytic cycle. pUL54 contains different domains that confer it polymerase, 3′ to 5′ exonuclease, as well as ribonuclease H activities ([@B285]). *IR1*, an 18-bp gene region, and activating transcription factor (ATF)-1, a transcription factor, contribute to the activation of *UL54* gene expression at early and late times of infection, respectively, possibly via interactions with other host and viral proteins ([@B124], [@B123]).

In addition to those six core replication proteins, IE2, UL36-38, and UL84 proteins were thought to be necessary for *Ori*Lyt-dependent DNA replication ([@B213]). However, UL36-38 gene products were demonstrated to be unnecessary thereafter, at least in telomerase-immobilized fibroblasts ([@B279]). pUL84 interacts with IE2 ([@B237]), resulting in transdominant inhibition of IE2, decreased early gene expression, and thus reduced DNA replication ([@B79]). [@B279] then reported that an active promotor within *ori*Lyt was repressed by IE2, and this negative effect was rescued by pUL84. pUL84 has also been shown to directly interact with transcriptional binding sites within *ori*Lyt ([@B120]). Moreover, pUL84 associates with pUL44 and nucleolin, and colocalizes with the proteins in the replication compartments at early times of infection ([@B18]). Posttranslational phosphorylation was also observed when pUL84 interacted with cellular casein kinase 2, and this association was required for DNA amplification ([@B78]). Together, pUL84 and IE2 are essential for *ori*Lyt-dependent DNA replication.

*UL45* gene encodes an inactive homolog of the large subunit of ribonucleotide reductase (RR) that catalyzes the reaction of dNTP synthesis ([@B187]). dNTP is essential for DNA replication, but whether the deletion of *UL45* causes viral growth defects is still controversial. The virus may develop other strategies to synthesize dNTP ([@B90]; [@B187]).

### Protein Expression {#S2.SS3.SSS2}

pUL69 is a member of the infected cell protein 27 (ICP27) family, and it contains a conserved folded domain termed ICP27 homology domain (IHD) that is required for mRNA nuclear export ([@B276]). Although pUL69 is able to bind to RNA, RNA binding is not critical for unspliced RNA export ([@B258]). Interactions with DEXD/H-box RNA helicases UAP56 and URH49 are essential for pUL69-mediated mRNA export ([@B151]). pUL69 can be phosphorylated by cyclin-dependent kinase (CDK)-9 and pUL97 ([@B86]). The accurate nuclear localization is attributed to the phosphorylation of pUL69 ([@B86]). Inhibition of CDK activity leads to the blockade of mRNA export ([@B198]).

Unlike most viruses that prevent cellular protein synthesis, cellular translation proceeds in HCMV-infected cells. Therefore, HCMV usurps translational factors from the host. pUL38 recruits and accumulates translational factors by regulating poly(A) binding protein (PABA), a protein that enhances the assembly of eukaryotic translation initiation factor 4F (elF4F) ([@B170]). pUL69 promotes translation by interacting with 4EBP1, preventing 4EBP1 binding to cap-binding complex, and thus relieving negative effects of 4EBP1 ([@B8]). RNA-dependent protein kinase R (PKR) recognizes viral dsRNA, and PKR is dimerized and autophosphorylated to be activated upon engagement. The active form of PKR phosphorylates eukaryotic initiation factor 2α (eIF2α), which inhibits its function in the initiation of translation. Therefore, PKR serves as an additional defense mechanism that reduces viral synthesis. HCMV counteracts this translation repression effect by expressing pTRS1 and pIRS1 that bind to PKR followed by PKR inactivation ([@B288]).

### Nuclear Egress {#S2.SS3.SSS3}

Nuclear egress is a process of transporting capsid containing newly synthesized and packaged viral genome out of the nucleus. HCMV wraps its genome into capsid to form the nucleocapsid, and insertion of viral genome into procapsid requires terminases (pUL56 and pUL89) that cleave two genomes in a concatemer. *UL77* encodes a capsid-associated structural protein that can bind to dsDNA and terminase subunits ([@B171]; [@B133]), and it has been demonstrated that pUL77 is necessary for viral DNA cleavage and packaging ([@B60]; [@B26]). pUL76 regulates the expression of *UL77*, but whether pUL76 has effects on nucleocapsid assembly is not known ([@B113]). It has been shown that pUL93 and portal protein pUL104 also participate in DNA package ([@B133]).

Nuclear egress complex (NEC), a heterodimer that consists of pUL50 and pUL53, transits nucleocapsid from the nucleus to the cytoplasm ([@B158]). Restriction of *UL53* gene expression and abnormal localization of pUL50 block nuclear egress in p53KO cells ([@B139]). NEC recruits pUL97, a protein kinase, to the nuclear rim where pUL50, pUL53, and pUL97 colocalize ([@B221]). Lamin A/C, the components of the nuclear lamina, are phosphorylated by pUL97, which are then disrupted to allow the escape of the nucleocapsid from the inner nuclear membrane ([@B11]; [@B221], [@B220]). Deletion of immunoglobulin heavy chain binding protein (BiP), an ER chaperone, gives rise to abnormal lamin phosphorylation at late time, implying that BiP is also involved in nuclear egress ([@B32]). The nucleocapsid budding across the inner nuclear membrane allows it to acquire a primary envelope and subsequently remove its envelope when budding through the outer nuclear membrane. Hence, it is commonly believed that two processes, envelopment and de-envelopment, are essential for nuclear egress ([@B174]; [@B84]). pUL96 assists pp150 to costabilize nucleocapsids during translocation from the nucleus to the cytoplasmic assembly compartment ([@B249]).

### Viral Assembly {#S2.SS3.SSS4}

The viral assembly complex (vAC), a juxtanuclear structure in the cytoplasm, is the site of viral tegumentation and envelopment, resulting in the formation of mature virus ([@B212]). The biogenesis of vAC is associated with the budding process from the secretory system, and viral pUL48 and pUL103 have been proposed to impact vAC development ([@B58]). The assembly site is largely altered from a compact structure to diffuse vacuoles in the absence of functional pUL97, indicating that *UL97* plays a role in vAC organization ([@B11]). pUL94 is in complex with pUL97 in vAC, and the interaction may contribute to viral assembly ([@B154]).

pUL94 allows correct localization and accumulation of pp28 in vAC ([@B193]). A threshold accumulation of pp28 is required for multimerization and viral envelopmentation ([@B218], [@B219]). Deletion of *UL99* leads to the production of non-enveloped viral particles ([@B229]). *UL26*-deleted virions also show hypophosphorylation of UL99-encoded pp28. Abnormal phosphorylation destabilizes pp28 ([@B179]), and stability of the intact viral particle is affected ([@B156]).

pp150--nucleocapsid complex transported to vAC is dependent on the microtubule motor system, in which BicD1 protein links pp150 (acting as a cargo) and dynein (that is a motor protein), and pp150 is actively transported in a monodirectional fashion ([@B103]). pUL71 contributes to the final step of the secondary envelopment of nucleocapsid. The oligomerization catalyzed by a basic leucine zipper-like domain on pUL71 is necessary for final envelopment ([@B172]). The viral particle can be wrapped by pUL71, which directs the complex to transport between the *trans*-Golgi network, viral assembly compartment, budding into multivesicular bodies and plasma membrane. pUL71 is localized toward the cytosolic phase of the cell membrane and covers recycling endocytic vesicles ([@B215]; [@B61]).

UL35 protein is also localized in the perinuclear region ([@B153]). More evidence based on expression of the *UL35* mutant virus in transfected cells has revealed decreased production of enveloped particles and disappearance of dense bodies (DBs), indicating a role of pUL35 in envelopment ([@B216]). Furthermore, the transport of envelope glycoprotein B is dependent on the binding of pUL35 and its interacting partner, sorting nexin 5 (SNX5) ([@B166]).

Three virus-related particles are formed and secreted from HCMV-infected cells. The first is the virion that contains the whole viral structure. Non-infectious enveloped particles that lack a viral genome are only produced in small amounts. DBs are commonly detected as incomplete viral particles that package envelope glycoproteins and some tegument proteins ([@B104]). pp65 (pUL83) is abundant in DBs ([@B265]). It was reported that DBs were able to induce apoptosis of Mo7e cells ([@B230]). *In vivo* study revealed that DBs could elicit production of antibodies against glycoproteins such as gH and gB as well as tegument proteins pp65 and pp150 ([@B189]). Moreover, DB-delivered pp65 could be presented by MHC-I, and this antigen presentation promoted cellular immune responses ([@B189]). DBs have also been shown to facilitate the maturation of dendritic cells and their capacity for antigen uptake and presentation ([@B214]). MiRNAs were detected within DBs and could be delivered into transfected cells ([@B177]). Recombinant DBs are vaccine candidates with efficient T cell and antibody responses ([@B16]).

### Anti-apoptosis {#S2.SS3.SSS5}

Fibroblasts infected with HCMV lacking the *UL38* coding sequence undergo extensively morphological changes and eventual apoptosis, prompting a role for pUL38 in preventing premature cell death ([@B253]). pUL38 binds to ubiquitin-specific protease 24 (USP24), a protein that mediates autophagic ferritin degradation in lysosomes. This association inhibits cell death as a result of the protection of lysosome integrity because the disturbance of iron homeostasis leads to lysosome instability ([@B245]). It has also been reported that pUL38 can relieve endoplasmic reticulum (ER)-mediated cell death independent of mTORC1 ([@B280]; [@B195]). *UL36* encodes viral inhibitor of caspase-8 activation (vICA), which modulates cell death in diverse pathways. pUL36 interacts with procaspase-8 and inhibits the formation of activated caspase-8 dimer in response to Fas-mediated apoptosis ([@B233]). It is also involved in caspase-independent apoptosis with unclear mechanisms ([@B169]). pUL44 and IE86 act concomitantly to block p53 transcriptional activity, thus overcoming cell cycle arrest and apoptosis to accomplish cellular DNA synthesis and protein production ([@B141]).

Envelope ([Table 3](#T3){ref-type="table"}) {#S2.SS4}
-------------------------------------------

Human cytomegalovirus is able to infect diverse cell types such as epithelial cells, fibroblasts, lymphocytes, monocytes, and macrophages, and this characterization of broad tropism is attributed to the envelope proteins that are believed to have roles in recognition, attachment, and fusion. Moreover, envelope mediators are the key to understanding cell-to-cell spread and HCMV dissemination. Entry into different cell types might be associated with concomitant effects from different combinations of envelope proteins. Three complexes termed glycoprotein complex I, II, and III (gCI, gCII, and gCIII) are present on the HCMV envelope.

###### 

HCMV envelope proteins.

  Protein                     Mapped gene             Composition                        Function(s)                                                                                                        References
  --------------------------- ----------------------- ---------------------------------- ------------------------------------------------------------------------------------------------------------------ --------------------------
  gB                          *UL55*                  gCI                                Recognition Attachment Fusion Viral entry Induction of humoral immune response                                     [@B266]; [@B235]
  gM                          *UL100*                 gCII                                                                                                                                                  [@B149]; [@B265]
  gN                          *UL73*                  gCII                                                                                                                                                  [@B55]; [@B265]
  gH                          *UL75*                  gCIII                                                                                                                                                 [@B98]
  gL                          *UL115*                 gCIII                                                                                                                                                 [@B98]
  gO                          *UL74*                  gCIII                                                                                                                                                 [@B98]
  gpUL128, gpUL130. gpUL131   *UL128, UL130, UL131*   In complex with gH/gL on envelop                                                                                                                      [@B207]; [@B251]
  gpUL116                     *UL116*                 Form complex with gH on envelop                                                                                                                       [@B35]
  gpRL13                      *RL13*                                                     Binds to IgG Fcγ                                                                                                   [@B241]; [@B147]; [@B52]
  gpTRL10                     *RL10*                                                     Unclear                                                                                                            [@B271]; [@B70]
  gp1                         *UL1*                                                      Has impacts on viral growth in epithelial cells but not fibroblasts                                                [@B224]
  gp48                        *UL4*                                                      Has no impact on viral growth in fibroblasts                                                                       [@B94]
  gp42                        *UL132*                                                    Has impacts on viral growth in fibroblasts Endocytosis of gp42 into virion is required for efficient replication   [@B236]; [@B138]

### gCI {#S2.SS4.SSS1}

gCI comprises two subunits, gp58 and gp116, which are the products of furin protease-cleaved glycoprotein B (gB), a precursor of 160 kDa ([@B266]). gB has been shown to play roles in viral entry into permissive cells ([@B105]) and as a target of neutralizing antibodies ([@B246]). It contains a disintegrin-like domain that recognizes integrins, and the integrin signals are likely to promote fusion since the delivery of pp65 is increased in the presence of gB disintegrin-like peptide, but attachment remains unaffected ([@B67]). Binding of gB also triggers alteration of host signaling pathways. Upon binding, induced expression of myeloid cell leukemia (Mcl)-1 protein enhances antiapoptotic effect in non-permissive progenitor myeloid cells ([@B199]). Small interfering RNA targeting Mcl1 exhibit increased cell death of HCMV-infected monocytes in comparison to mock infection and use of control siRNA ([@B43]). Moreover, blockade of epithelial growth factor receptor (EGFR) with specific neutralizing antibodies and pharmacological inhibitors results in the downregulation of Mcl-1 gene expression and shows similar level of cell viability to mock infection. Therefore, EGFR in monocytes appears to be an important receptor that interacts with HCMV. EGFR is further proved to be required for mediating viral entry into CD34^+^ progenitor cells ([@B128]). In fibroblasts, however, HCMV infection fails to stimulate EGFR phosphorylation and activation ([@B106]). Viral entry is not affected in fibroblasts, epithelial and endothelial cells pretreated with EGFR antibodies ([@B106]). The roles of EGFR are still controversial. Further, host cells, at least monocytes, upregulate inflammatory gene expression such as interleukin-1β (IL-1β) upon gB engagement ([@B283]).

There are various polymorphic sites along the gB-encoded *UL55* gene containing 906 amino acids, with the most variable regions present in the N-terminus, C-terminus, and furin cleavage sites ([@B240]). It has been demonstrated that the genotype of gB differs with respect to the geographic distribution ([@B291]). For example, compared with patients from California, an increase in the gB4 genotype has been observed in immunocompromised patients from Italy ([@B291]). Infection by HCMV with different gB genotypes may not share a comparable natural disease course ([@B206]). gB1 and gB2 types are often seen in patients with transplantation and infection with human immunodeficiency virus (HIV), respectively ([@B73]; [@B223]). The 275Y variants of gB expressed on the AD169 strain promote fusogenicity with activation of caspase 2 and the DNA damage response since the 275D variants show less syncytium formation and an inability to trigger caspase 2 ([@B250]). Whether gB genotypes are associated with cell tropism are largely elusive.

### gCII {#S2.SS4.SSS2}

gCII is designated as a complex that is formed covalently and non-covalently by gM together with gN, which are the products of *UL100* and *UL73* ORFs, respectively ([@B160]; [@B265]). Formation of the gM/gN complex in the ER is required for transport and intracellular trafficking of the heterodimer to the mature virion assembly center ([@B161]). Binding to cell surface heparan sulfate proteoglycans (HSPGs) is the initial step in which virus tethers and attaches to the host ([@B51]). gCII ([@B122]) and soluble gB ([@B27]) are interaction partners of heparin, and the interactions thus facilitate viral attachment and entry. Similar to gB, gM and gN elicit humoral responses in which neutralizing antibodies are produced ([@B222]). Anti-gM/gN antibodies may be able to recognize HCMV unlimited by strain specification since anti-gM/gN IgG antibodies generated from AD169 can bind to the Toledo strain ([@B225]).

### gCIII {#S2.SS4.SSS3}

gCIII contains the gH/gL/gO complex, a high-molecular-weight complex ([@B131]). This is further complicated by the fact that co-expression of the *UL75* (gH), *UL115* (gL), and *UL74* (gO) genes does not readily result in the formation of the tripartite complex ([@B98]). gH binding triggers activation of transcription factors such as NK-κB, a process that can be blocked by anti-gH neutralizing antibodies ([@B284]). The *UL74* sequence shows variations, leading to a growing recognition of the functional importance of gO ([@B186]). Further studies have described an increased sensitivity of *UL74*-deleted HCMV-infected fibroblasts in the context of anti-HCMV serum, anti-gB antibodies, and anti-gH antibodies ([@B118]). In addition to the gH/gL/gO complex, gH/gL interact with UL128--131 gene products. The different constitutions of the two complexes are associated with cell-specific tropism. The gH/gL/gO complex is required for entry and dissemination between fibroblasts, while viral entry into epithelial and endothelial cells requires the gH/gL/UL128--131 complex to bind to cognate receptors ([@B97]; [@B269]; [@B2]). In addition, UL128--131A gene products are required for efficient internalization into monocytes via integrin-mediated signaling ([@B181]), and they are crucial for infection of monocytes ([@B244]) and dendritic cells ([@B80]).

### Other Proteins {#S2.SS4.SSS4}

[@B241] assumed that the highly glycosylated RL13 protein may be a surface envelope protein. Its role on envelope was further studied by another group ([@B52]). Fcγ signals could be detected though flow cytometry in *RL13*-expressed HEK293T cells that were exposed to DyLight 649-conjugated human Fcγ, suggesting that RL13 interacted with Fcγ. This result was further confirmed by confocal microscopy analysis that showed colocalization of Fcγ and RL13 ([@B52]). Therefore, RL13 has Fc binding abilities. Four viral encoded G-protein coupled receptors (GPCRs) are also viral membrane proteins, which have been intensively reviewed ([@B135]; [@B72]). Their functions are briefly summarized in [Table 4](#T4){ref-type="table"}.

###### 

Viral GPCRs.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein   Mapped gene   Function(s)                                                                                      References
  --------- ------------- ------------------------------------------------------------------------------------------------ -------------------------------------------
  pUL33     *UL33*        ➢ Co-localizes, interacts and further blocks US28-induced NK-κB activation\                      [@B71]; [@B40]; [@B260]; [@B247]; [@B264]
                          ➢ Enhances transcription mediated by cAMP responsive element\                                    
                          ➢ Forms a complex with pUL78, host CCR5 and CXCR4, and impairs CXCR4 effects\                    
                          ➢ Has oncomodulatory properties                                                                  

  pUL78     *UL78*        ➢ Co-localizes, interacts and further blocks US28-induced NK-κB activation\                      [@B175]; [@B260]; [@B183]
                          ➢ Form a complex with pUL33, host CCR5 and CXCR4, and impairs CXCR4 effects\                     
                          ➢ Has impacts on viral growth in epithelial and endothelial cells but not fibroblasts            

  gpUS27    *US27*        ➢ Promotes CXCL12/CXCR4 signaling\                                                               [@B71]; [@B142]; [@B22]; [@B23]; [@B261]
                          ➢ Increases surface CXCR4 level\                                                                 
                          ➢ Facilitates CXCR4 internalization after CXCL12 binds\                                          
                          ➢ Stimulates expression of stress response genes\                                                
                          ➢ Increases DNA replication\                                                                     
                          ➢ Induces pro-survival factors such as Bcl-x                                                     

  pUS28     *US28*        ➢ Acts as chemokine receptors, has multiple ligands and activates multiple signaling pathways\   [@B71]; [@B136], [@B135]; [@B287]; [@B72]
                          ➢ Chemokine internalization\                                                                     
                          ➢ Promotes survival\                                                                             
                          ➢ Activates MIEP in differentiated cells\                                                        
                          ➢ Promotes latency in undifferentiated cells                                                     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

Different Significances of Virion-Carried Molecules in Primary Infection and Reactivation {#S3}
=========================================================================================

Roles of pp71 in Primary Infection and Reactivation ([Figure 1](#F1){ref-type="fig"}) {#S3.SS1}
-------------------------------------------------------------------------------------

Lifelong HCMV infection is attributed to its latency in healthy individuals. Single-cell transcriptomic analysis found that the transcription program in the latently infected cells mirrors that at the late phase of lytic replication, but the latency-associated expression level is low ([@B227]). Viral abilities to re-express lytic genes from the quiescent form in response to certain stimuli are associated with complications such as severe pneumonia and gastrointestinal disease following transplantation ([@B286]). CD34^+^ HPCs and CD14^+^ monocytes do not provide a platform for viral replication, and undifferentiated cells are considered to be the latent reservoirs of HCMV ([@B173]; [@B126]). Nuclear pp71 can be detected by immunofluorescence in normal human dermal fibroblasts (NHDFs), the permissive cells for HCMV lytic replication. By contrast, pp71 is retained in the cytoplasm instead of the nucleus of HPCs ([@B209]). Interestingly, the process of viral entry into CD34^+^ HPCs by macropinocytosis does not allow pp71 to escape from endosomes, and endosome retention is at least one possible mechanism that ensures the cytoplasmic localization of pp71 in HPCs ([@B144]). Cytoplasmic localization of pp71 has also been observed in NTERA-2 (NT2) cells that are incompletely differentiated cell lines ([@B188]). The pp71 subcellular localization is crucial for its transactivities and therefore associated with the replicative or latent phase. The underlying mechanism is largely determined by the interaction of pp71 with components of the ND10 ([@B95]).

![Roles of pp71 in the lytic and latent phase. The **left panel** shows lytic gene expression. Nuclear pp71 is capable of promoting pUL35 to recruit PML, an ND10 component that has impacts on correct localization of Daxx and Sp100. pp71 interacts with Daxx and induces Daxx for degradation in a proteasome-dependent manner. pp71 transactivates IE gene expression, and IE products disrupt ND10. pp71 also has abilities to induce Rb degradation, a process that contributes to relieve Rb-mediated cell cycle block. The **right panel** shows the latent state and reactivation. pp71 is retained in the cytoplasm or endosome rather than the nucleus. ND10 components represent an intrinsic defense mechanism. Daxx, PML, and bound transcription factors recruit histone deacetylases, resulting in viral gene silencing. LUNA-mediated reactivation is shown in a black circle. LUNA contains isopeptidase activity that deSUMOylates PML and disrupts PML-induced recruitment of Daxx and Sp100. Therefore, LUNA promotes reactivation.](fmicb-11-01511-g001){#F1}

Promyelocytic leukemia protein (PML)-associated nuclear bodies (also known as ND10), subnuclear spherical and punctate structures that are, on average, 0.3 to 0.5 μm in size ([@B3]), are thought to be the location for input viral DNA accumulation ([@B107]). Death domain-associated protein (Daxx), one of the most important components in ND10, acts as an intrinsic defense mechanism against HCMV by restriction of viral gene expression as demonstrated by the inhibition of viral replication in cells overexpressing Daxx ([@B37]). Daxx-induced HCMV transcriptional repression promotes the establishment of latent states ([@B209]). Daxx and other ND10 proteins that bind to transcriptional factors are able to recruit histone deacetylases (HDACs) ([@B96]; [@B168]). The major immediate early promotor (MIEP)-bound histones are unacetylated in undifferentiated cells ([@B201]), and thus MIEP that drives lytic replication is transcriptionally inert. Downregulation of Daxx results in failed formation of heterochromatin and increased IE gene expression ([@B277]). Moreover, Daxx together with ATRX forms a complex that is considered to be a H3.3 histone chaperone that affects H3.3 deposition on heterochromatin ([@B145]). In addition to Daxx, other components of ND10, including PML and Sp100, also contribute to viral genome repression ([@B83]). Compared with the knockdown of Daxx alone using siRNA, triple deletion of Daxx, PML, and Sp100 can more efficiently inhibit gene expression and viral production ([@B83]). In the absence of PML, Daxx and Sp100 show a dispersed distribution and disrupted colocalization ([@B252]).

By two-yeast hybrid system screening ([@B95]) and immunoprecipitation ([@B95]; [@B110]), pp71 has been found to be an interactor with Daxx. Hofmann et al. also confirmed colocalization of Daxx and pp71 ([@B95]). A mutant version of pp71 that lacks binding ability to Daxx is unable to transactivate IE expression ([@B95]). Therefore, the association of pp71 and Daxx is pivotal for the functions of pp71. pp71 proteins are accumulated in the nucleus prior to IE2 transcription ([@B110]). The following study reported that pp71 was able to induce Daxx degradation through proteasome, independent of ubiquitin ([@B100]). Daxx degradation is critical for pp71 functions in transactivation since Daxx plays roles in the recruitment of HDACs, heterochromatin formation, and transcriptional repression ([@B96]; [@B277]). Acetylation of MIEP-associated histones was detected when latently infected CD34^+^ progenitor cell terminally differentiated into dendritic cell, a permissive cell type that supports the HCMV productive phase ([@B201]). Furthermore, pp71 also promotes Daxx SUMOylation, but this posttranslational modification is unable to affect pp71 transactivity ([@B101]). SUMOylation of PML is required to recruit Daxx ([@B108]), but the effect of SUMOylation still needs to be investigated. The interplay between ND10 and pp71 is further complicated by evidence showing that pp71 facilitates the UL35 gene products pUL35 to form UL35 nuclear bodies, which are capable of recruiting PML, Daxx, and Sp100 ([@B210]). The transfected cells infected with mutant virus that harbors deletions in the *UL35* gene show decreased IE gene expression ([@B216]). UL35a protein, a short-sized UL35 gene product, however, shows reduced formation of UL35 nuclear bodies and contributes to pp71 cytoplasmic localization ([@B210]). Indeed, previous research has reported that pUL35a inhibits pp71-mediated MIEP activation ([@B153]). However, unlike pUL35 that was found in virions, pUL35a is not packaged into the mature virion, and its transcripts are detected 4 h after infection ([@B153]). It is likely that pUL35 plays roles earlier than pUL35a as pUL35 is a preexisting protein. After pp71 degrades Daxx and activates IE gene expression, IE gene products disperse and disrupt ND10 ([@B134]; [@B109]). A recent study has reported that LUNA-mediated deSUMOylation is required for PML dispersal ([@B194]).

Less efficient reactivation has been detected in dendritic cells that are differentiated from CD34^+^ progenitor cells infected with LUNA-defective HCMV, compared to wild-type HCMV infection ([@B194]). In contrast, viral production in fibroblasts shows no differences between wild-type and LUNA knockdown group ([@B194]). Further, in comparison to wild type, PML knockdown results in increased numbers of cells that prime IE gene expression of fibroblasts ([@B252]), but no distinction in IE-forming units in the reactivation model ([@B194]). Heterogeneous cell fusion experiments in which NHDFs form syncytia with viral-infected NT2 cells showed that pp71 proteins that were previously localized in the NT2 cytoplasm were detected in nuclei in syncytia, indicating that terminally differentiated cells provide factors that promote pp71 nuclear accumulation ([@B188]). As discussed above, pp71 cytoplasmic or nuclear localization contributes to the establishment of the latent or replicative phase, respectively. However, reactivation can occur at various times after the initial infection. This process is unlikely to utilize the pp71 retained in the cytoplasm. Moreover, latency-associated pp71 expression is not significantly high ([@B46]). Whether pp71 is crucial for IE gene expression during reactivation is unclear, and this knowledge may hold the key to understanding HCMV-associated disease and even mortality posttransplantation. Together, there might be differences in the initiation of IE transcription in primary infection and reactivation.

Roles of pUS28 in Primary Infection and Reactivation {#S3.SS2}
----------------------------------------------------

pUS28, a virally expressed GPCR, shares homology with human chemokine receptor ([@B76]) and is able to interact with diverse CC and CX(3)C chemokines ([@B76]; [@B132]). The *US28* gene is transcribed in both the lytic and latent phases ([@B17]). Recent transcriptome analysis has confirmed latency-associated transcription in both natural CD34^+^ HPCs and experimentally latent models ([@B46]). Deletion of *US28* results in the failed establishment of latency. Also, in undifferentiated monocytes, MIEP is associated with phosphorylated H3 (a histone marker of transcriptional activation) and heterochromatin protein 1 in the absence and presence of US28 respectively ([@B136]). These findings suggest that pUS28 plays a role in the promotion of the latent phase. Moreover, the authors further found that functional pUS28 was able to increase MIEP activities of differentiated cells ([@B136]). Together, these data show that pUS28 has different effects on the lytic and latent phases, and activities of pUS28 are heavily dependent on the differentiation states. The point mutation R129A in US28 results in an inability to activate or repress signaling pathways, and Y16F leads to pUS28 that is incapable of binding to chemokines. Expression of US28 with Y16F by lentivirus complements pUS28-mediated latency, whereas R129A does not, demonstrating that Y16F does not affect pUS28-induced latency, and signaling pathway alteration is linked to the effects of pUS28 on latency establishment ([@B136]). Further, pUS28 is likely to dephosphorylate MAPK and NK-κB factors in undifferentiated cells, at least partially contributing to the establishment of latency. It has opposite impacts on differentiated cells, namely, hyperphosphorylation of signaling molecules to facilitate lytic infection ([@B136]). A recent report discovered that HCMV forces HPCs into a monocyte subset characterized by a longer lifespan and immunosuppressive phenotype via STAT3-iNOS-NO cascade to achieve latency ([@B287]). Deletion of *US28* leads to STAT3 inactivation and subsequent failure of latent establishment, indicating that pUS28-mediated STAT3 phosphorylation is essential for latency ([@B287]).

Roles of Virion-Carried Molecules in Nuclear Targeting During Primary Infection {#S3.SS3}
-------------------------------------------------------------------------------

Nuclear targeting is a process of transportation of incoming nucleocapsid to host nucleus, and this process is dispensable for reactivation. The bipartite NLS of pUL48 mediates nuclear targeting, a process that targets the nucleocapsid toward the host nucleus and releases the viral genome into the cell nucleus ([@B31]). pUL48 may cooperate with pUL47 to promote disassembly of the nucleocapsid and enhance the release of viral DNA from the capsid ([@B15]). pUL47 is a pUL48-binding protein, and the interaction facilitates cleavage of isopeptide bonds via the deubiquitylating activity of pUL48 ([@B262]). A mutant virus that lacks deubiquitinating activity shows decreased replication and dissemination as a result of reduced autodeubiquitination ([@B129]).

Tegument proteins preserve the integrity of the capsid that houses an incompatible large genome. The 150-kDa phosphoprotein encoded by the *UL32* gene, a second abundant component of the tegumental layer, was found to interact with the triplex on the capsid and to extend toward the SCP ([@B282]). The subcellular localization of pp150---nucleus or cytoplasm---is still controversial, and it may accompany the capsid and transit from nucleus to cytoplasm ([@B212]; [@B211]). Nevertheless, pp150 is thought to be involved in nuclear targeting during primary infection, organization of the assembly compartment, tegumentation, and virion egress during late infection due to its extensive structural associations with the nucleocapsid ([@B10]; [@B248]; [@B103]).

Roles of Virion-Carried Molecules in Host Cell Cycle Regulation {#S3.SS4}
---------------------------------------------------------------

Viral replication is a complex cascade that requires the host cells to provide replicative factors and nutrients, and those substances supplied during cell division are not sufficient for viral growth, especially for HCMV with a long replication cycle. Hence, HCMV develops strategies to arrest host in the G1/S phase to accomplish the whole lytic replication cycle. In primary infection, virally delivered factors can be readily used to regulate the host cell cycle.

Viral pUL21a destabilizes cyclin A2 via a conserved cyclin A2 binding motif, arginine-x-leucine (RxL), via proteasome-dependent degradation to arrest host cell cycle progression ([@B34]). Overexpression of cyclin A2 renders host cells entry into mitotic phase ([@B63]). pUL21a further modulates the host cell cycle by degrading anaphase-promoting complex/cyclosome (APC/C) subunits that serve as an E3 ubiquitin ligase that digest certain proteins in the G1 and M phase to regulate the cell cycle ([@B65]). pp150 mutant virus that lacks binding ability to cyclin A2 is unable to arrest hosts in the S/G2 block, but cell gene expression is restricted at the G2/M phase ([@B273]). Double mutation of pp150 and pUL21a, both of which are unable to interact with cyclin A2, results in unrestricted G2 and mitotic entry ([@B273]). Those data indicate that pp150 and pUL21a concomitantly reprogram the cell cycle ([@B273]). In response to stress signaling such as viral infection, tuberous sclerosis protein complex 2 (TSC2) is activated, which in turn blocks mTORC1 activities, halting cell growth ([@B178]). mTORC1 can also be activated by pUL38 in a TSC2-independent pathway, suggesting that pUL38 is able to modulate cell growth ([@B178]; [@B13]). pUL69 has also been reported to induce G1 blockade ([@B157]; [@B92]).

If the host is default to pass through the S/G2 phase and undergo subsequent division, HCMV replication is decreased to wait for a time that allows sufficient viral growth. Cell-cycle-associated IE gene repression is independent of intrinsic defense mechanisms such as PML ([@B293]). The viral reproductive cycle can be inhibited with high levels of cyclin A in the S/G2 phases, and the interaction between pp150 and cyclin A is essential for inhibition ([@B273]). pp150--cyclin A2--CDK activities in the S/G2 phases interfere with viral IE gene expression by blocking IE gene expression and affecting IE mRNA splicing ([@B184]; [@B24]). Therefore, once the sensor protein pp150 binds to cyclin A, HCMV transiently shuts down IE gene expression to ensure that viral lytic replication does not take place in the time course of host cell division ([@B24]).

In the quiescent state, retinoblastoma (Rb) forms a complex with E2F, inhibiting the expression of E2F-responsive genes and subsequent cell cycle progression. Rb ([@B99]) and its family members ([@B117]) are phosphorylated by viral pUL97. Hyperphosphorylation and inactivation of Rb by pUL97 activates E2F-mediated transcription and cell cycle progression ([@B115]). Moreover, Rb interacts with ND10-associated proteins ([@B5]), enhancing the transcriptional repression of the viral genome ([@B64]). Hyperphosphorylation of Rb by pUL97 relieves this negative effect in a PML-dependent manner ([@B64]). Additional mechanisms are also involved in the regulation of Rb family members. pp71 degrades Rb proteins by the proteasome ([Figure 1](#F1){ref-type="fig"}; [@B121]).

Reactivation is highly dependent on cell differentiation states. Upon treatment of interleukin-4 (IL-4) and granulocyte macrophage/colony stimulating factor (GM/CSF), experimentally latent CD14^+^ monocytes differentiate into immature dendritic cells (DCs) that do not display robust lytic replication ([@B200]). Additional treatment of lipopolysaccharide (LPS) and interleukin-6 (IL-6) transforms immature cells into mature DCs that support HCMV reactivation, suggesting that differentiation and inflammation are two leading stimuli for viral reactivation ([@B200]). Thus, reactivation occurs in final differentiated cells and relatively independent of regulation of the host cell cycle.

HCMV Protein Related Anti-Viral Therapy {#S4}
=======================================

The most common antiviral drugs used to control HCMV infection are ganciclovir (GCV), valganciclovir, foscarnet, and cidofovir. Valganciclovir, the prodrug of ganciclovir, can be metabolized to GCV, an analog of nucleoside guanosine. GCV is activated by phosphorylation catalyzed by pUL97 and cellular kinases to form ganciclovir triphosphate, terminating viral DNA synthesis by incorporation into the newly produced DNA strand and inhibition of pUL54 DNA polymerase activities ([@B167]). Therefore, mutations in *UL54* or *UL97* or both give rise to drug resistance, with more cases related to *UL97* mutations, for example, deletions of codon 594 in the UL97 genes ([@B125]) and point mutations such as M460V/I, H520Q, N510S, C592G and C603W ([@B49]; [@B12]). Cidofovir is an analog of deoxycytidine monophosphate, which is further phosphorylated to a deoxycytidine triphosphate analog. Post-hematopoietic stem cell transplantation (HSCT) patients generally do not benefit from brincidofovir, a lipid conjugated cidofovir, applied for HCMV prophylaxis. All-cause mortality was 15.5 and 10.1% in the brincidofovir and placebo group, respectively ([@B165]). A similar approach is employed by cidofovir triphosphate to block pUL54 activities. Foscarnet is also an alternative choice because it inhibits pyrophosphate binding site on pUL54, and thus, pyrophosphate is not able to be cleaved from nucleotides. These available antiviral agents are limited by resistance, poor bioavailability as well as acute and long-term adverse effects such as severe myelosuppression. Most anti-HCMV drugs in widespread use were developed to target pUL54 polymerase, while maribavir interacts with pUL97 and disrupts the kinase activities of pUL97 ([@B197]). Maribavir had comparable effects to valganciclovir in the control of HCMV viremia in the posttransplantation settings in a phase two trial ([@B162]). However, it is difficult to determine or distinguish whether the HCMV viremia results from primary infection or reactivation. Therefore, whether the drug has different efficacies in primary infection and reactivation are unknown. Letermovir targets pUL56, the large subunit of the terminase complex that plays roles in DNA cleavage/packaging ([@B150]). In a phase 2 clinical trial that administered letermovir as prophylaxis therapy to HCMV-seropositive patients after HSCT, letermovir (at a dose of 120 and 240 mg per day) was shown to significantly reduce HCMV reactivation compared with placebo ([@B44]). ASP0113, a DNA-based vaccine, contains plasmids encoding gB and pp65 ([@B234]). However, the prevention efficacy is not significant in D^+^ /R− kidney transplantation ([@B267]). gB vaccine with MF59 adjuvant has been reported to reduce congenital primary infection ([@B185]). Moreover, gB vaccine was also effective for decreasing reactivation rates in D^+^ /R− post HSCT ([@B88]).

New methods have been developed following advances in molecular biology. *In vitro* studies have shown a promising therapeutic method using siRNAs targeting gene transcripts of *UL54*, *UL97*, and *UL122/123*. Despite the high efficacy *in vitro*, no *in vivo* analysis has been published ([@B91]). However, other studies have demonstrated that siRNA targeting *UL54* is less effective and has limited utility ([@B226]). Viral GPCR pUS28 is expressed at the host membrane to interact with chemokines and triggers internalization once engaged. F49A-fusion toxin proteins (F49A-FTP) can bind to pUS28 to subsequently mediate endocytosis. The coupled toxin has cytotoxic effects on target cells. This novel strategy was shown to efficiently kill targets with lytic infection ([@B238]) and to reduce reactivation of cells latently infected with HCMV ([@B137]).

Summary {#S5}
=======

Human cytomegalovirus infects large populations and becomes dormant in primitive progenitor cells. Reactivation in transplant recipients can lead to severe CMV disease and cause death. Usage of virion-carried mediators (especially surface glycoproteins and tegument proteins) is associated with biological processes during primary infection, latency, and reactivation. Viral envelope proteins determine cell tropism in primary infection and dissemination. They act as targets for neutralizing antibodies and vaccines. Tegument links the envelope and nucleocapsid. Although the limited amounts of some tegument proteins are not sufficient to complete associated biological processes, they still participate in viral life cycle and merit discussion. Unlike primary infection in which virion-carried proteins can assist HCMV to reconcile the host to favor viral proliferation, they cannot be readily used by viruses in the context of reactivation. Those packaged proteins such as pp71 are differentially used in primary infection and reactivation. Some biological processes, such as nuclear targeting, are unique to primary infection, and thus proteins involved in such processes predominantly play roles in primary infection rather than reactivation. The mechanism by which HCMV rapidly produces molecules that enhance re-expression of lytic genes holds the key to understanding reactivation. Moreover, although the virus becomes latent in HPCs upon initial infection, the strategies used by HCMV to dampen immune response toward virion-delivered foreign molecules such as glycoproteins on envelope and tegument proteins remain to be understood.
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